{
  "url": "https://www.law.cornell.edu/regulations/new-york/9-NYCRR-9960.1",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 9 ยง 9960.1 - Covered drug",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 9 ยง 9960.1 - Covered drug\n\nState Regulations\n(a) Definitions. For purposes of this Part, the following terms shall have the\nfollowing meanings: (1)\n\nDepartment means the\n\nNew York State Department of Health. (2)\n\nCommissioner means the New York State\n\nCommissioner of Health. (3)\nEPIC\nmeans the Elderly Pharmaceutical Insurance Coverage Program established\npursuant to section 19-K of the Executive Law. (4)\n\nEligible participant means a person\ndeemed eligible to receive benefits coverage under EPIC. (5)\n\nLicensed physician means a legally\nauthorized prescriber of drugs. (6)\n\nExcluded drug means any drug package, dosage form or administration deemed to\nbe excluded as a covered benefit under EPIC pursuant to section\n9960.3\nof this Part. (7)\n\nDrug Application\n\nInformation form means a form developed by the department for the purpose of\ncollecting information from licensed physicians and used by the department in\ndetermining coverage of excluded drugs under EPIC. (8)\n\nContractor means the private, not-for-profit, or proprietary corporation which has entered into a contract\nwith EPIC to assist in carrying out the provisions of EPIC. (b) To be eligible for an\ninsurance benefit, a prescription drug shall be dispensed subject to a legally\nauthorized prescription from a registered pharmacy. (c) Insulin, insulin syringes and insulin\nneedles shall qualify as a covered drug benefit. (d) Dispensing of a covered drug shall be in\nquantities ordered by the prescriber not to exceed a 30-day supply or 100\ndoses, whichever is greater. (e) A\ncovered drug shall not include any drug product: (1)\n(i) where the Federal Food and Drug Administration (FDA) of the Federal Department\nof Health and Human Services (HHS) has issued any notice of a proposed order\nindicating that there is a lack of substantial evidence that such drug product\nwill have the effect it purports or is represented to have under the conditions\nof use prescribed, recommended or suggested in its labeling until the secretary\nof HHS withdraws such order; or\n(ii)\nwhich the FDA determines to be\nidentical, related, or similar to the drug product identified in subparagraph\n(i) of this paragraph until such time as the secretary of HHS withdraws the\norder identified in subparagraph (i) of this paragraph. (2)\nmarketed by a company without FDA\napproval where the FDA finds its approval is required; (3)\nwhich is generally available without a\nphysician's prescription, including vitamins, except for insulin; (4)\nproperly administered only by a\nphysician, dentist or podiatrist as indicated in the official labeling of such\ndrug product; (5)\ngenerally\navailable free of charge to eligible participants; (6)\nmarketed as a therapeutic agent with\nofficial labeling which states that the product is contraindicated by virtue of\nage or therapeutic condition for program participants; (7)\nany device for the aid or correction of\nvision; or\n(8)\nfor which a\npharmaceutically and therapeutically equivalent drug is available in a less\nexpensive package, or form of dosage or administration as identified and\ndetermined according to specified procedures delineated in section\n9960.3\nof this Part. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 9\nยง\n9960.1\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "regulation",
  "source_index": 42964
}